Biogen Idec Inc. (BIOGEN) - 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2008. Biogen Idec Inc. is a global biotechnology company focused on therapeutic areas with high unmet medical needs. The company's primary marketed products include AVONEX (multiple sclerosis), RITUXAN (oncology/autoimmune, via collaboration with Genentech), TYSABRI (multiple sclerosis), and FUMADERM (psoriasis). The company operates as a single business segment.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 |
|---|---|---|
| Total Revenues | $1,093.0 million | $3,028.6 million |
| Net Income | $206.8 million | $576.5 million |
| Diluted EPS | $0.70 | $1.95 |
| Operating Cash Flow (9mo) | $1,155.2 million | |
| Cash & Cash Equivalents | $1,010.7 million (as of Sep 30, 2008) | |
| Working Capital | $1,653.2 million (as of Sep 30, 2008) | |
| Total Debt (Current + Long-term) | $1,052.6 million (as of Sep 30, 2008) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 38.5% year-over-year for the three months ended September 30, 2008, and 33.0% for the nine-month period. This was driven by significant growth in TYSABRI sales (up 172% QoQ and 209% YoY for nine months) and AVONEX (up 26% QoQ and 20% YoY for nine months), as well as increased profits from the unconsolidated joint business with Genentech (RITUXAN).
- Profitability: Net income rose 73% for the quarter and 32% for the nine-month period compared to 2007. Operating income increased significantly due to revenue growth outpacing expense increases.
- Debt Restructuring: In March 2008, the company issued $1.0 billion in Senior Notes ($450M due 2013 and $550M due 2018) to repay a $1.5 billion term loan facility. Consequently, current portion of notes payable dropped from $1.51 billion (Dec 31, 2007) to $10.2 million (Sep 30, 2008), while long-term notes payable increased to $1.04 billion.
- Investment Impairments: The company recognized $24.7 million in realized losses and impairments on marketable securities (primarily mortgage and asset-backed securities) in the first nine months of 2008, compared to $6.2 million in the prior year period.
- Share Repurchases: The company repurchased approximately 9.0 million shares of common stock for $559.8 million during the first nine months of 2008.
Guidance, Outlook, Risks, and Unusual Items
- TYSABRI Safety Concerns: In July 2008, the company disclosed two confirmed cases of progressive multifocal leukoencephalopathy (PML) in patients taking TYSABRI. While the company continues to monitor growth, this safety issue represents a significant risk to future sales and market acceptance.
- Effective Tax Rate: The effective tax rate for the nine months ended September 30, 2008, was 32.9%, compared to 29.0% in the prior year. Management expects the full-year 2008 rate to be between 31% and 33%, noting potential unfavorable impacts from Massachusetts tax law changes and international restructuring.
- Manufacturing Commitments: The company is constructing a large-scale biologic manufacturing facility in Hillerod, Denmark, with contractual commitments of approximately $240.4 million. The project's success is dependent on TYSABRI market acceptance.
- Legal Proceedings: The company is involved in various litigation matters, including a class action lawsuit regarding TYSABRI (dismissed and affirmed on appeal), investigations into RITUXAN promotion by the DOJ, and multi-district litigation regarding Medicaid pricing. Additionally, an arbitration with Genentech regarding the collaboration agreement is ongoing.
- Financial Market Risks: The bankruptcy of Lehman Brothers reduced the company's revolving credit facility availability from $400 million to $360 million. The company also faces risks related to the valuation of its marketable securities portfolio due to global financial market instability.
Key Facts for Investor Verification
- TYSABRI Sales Trajectory: Verify if the two confirmed PML cases have materially impacted prescription rates or market share in the multiple sclerosis sector.
- Debt Service Obligations: Confirm the impact of the new $1.0 billion Senior Notes on future interest expense and cash flow availability.
- Investment Portfolio Health: Assess the remaining exposure to mortgage-backed and asset-backed securities and the potential for further impairment charges given market volatility.
- Manufacturing Capacity: Monitor the progress and licensing status of the Hillerod, Denmark facility, as delays could constrain TYSABRI supply.
- Legal Exposure: Track the status of the DOJ investigation into RITUXAN promotion and the Genentech arbitration, as outcomes could affect revenue sharing or result in significant liabilities.